FDA Approves First Oral PCSK9 Inhibitor to Lower Cholesterol, Offering Alternative to Injectables

The US Food and Drug Administration has authorized the first-ever oral medication in a highly potent class of cholesterol-lowering drugs, marking a significant milestone in cardiovascular care. The drug, developed by Merck and branded as Lipfendra (enlicitide), is approved for adults with high cholesterol who need further reductions despite standard treatments like statins.[1][2]

Until now, therapies targeting the PCSK9 protein have only been available as subcutaneous injections. While highly effective, these injectable biologics—such as Amgen's Repatha and Regeneron's Praluent—have seen limited uptake over the past decade due to high costs, insurance hurdles, and patient reluctance to self-inject.[3][4]

Lipfendra shifts this paradigm by delivering the same biological mechanism in a 20-milligram, once-daily tablet. The approval covers adults with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), a genetic disorder that causes dangerously high levels of low-density lipoprotein (LDL) cholesterol from birth.[1][2][6]

To understand why an oral PCSK9 inhibitor is a breakthrough, it helps to look at how the body clears cholesterol. The liver removes "bad" LDL cholesterol from the bloodstream using specialized receptors on the surface of its cells.[4]

However, a naturally occurring protein called PCSK9 binds to these receptors and marks them for destruction, reducing the liver's ability to clear cholesterol. By inhibiting the PCSK9 protein, these drugs allow more receptors to survive and pull cholesterol out of the blood.[4]

Developing a pill to block PCSK9 was notoriously difficult. The protein interaction surface is large and flat, making it a poor target for traditional small-molecule drugs. Merck solved this by engineering a "macrocyclic peptide"—a larger, ring-shaped molecule that can bind tightly to the PCSK9 protein but is still stable enough to survive the digestive tract and be absorbed into the bloodstream.[2][3][4]

The clinical evidence supporting the approval comes from the Phase 3 CORALreef trial program. In the CORALreef Lipids trial, which enrolled over 2,900 patients with a history of or high risk for cardiovascular disease, Lipfendra reduced LDL cholesterol by an average of 56% compared to a placebo over 24 weeks.[2][4]

A separate trial, CORALreef HeFH, focused specifically on patients with the inherited genetic form of high cholesterol. In that study, the oral medication achieved a placebo-adjusted LDL reduction of 59%.[2]

These numbers are striking because they nearly perfectly match the efficacy of the injectable monoclonal antibodies that have been on the market for years. Achieving biologic-level potency with a daily pill is a rare pharmacological feat, offering a seamless transition for patients who require aggressive lipid lowering but refuse needles.[4][5]

The transition to a pill does come with a specific administration caveat. Because the macrocyclic peptide can interact poorly with food in the digestive tract, patients must take Lipfendra with water and wait at least 30 minutes before eating or drinking anything else, including coffee. Pharmacists note that establishing this morning routine will be critical for patients to achieve the full cholesterol-lowering benefits.[3][6]

Pricing and access have historically been the Achilles' heel of the PCSK9 inhibitor class. When the first injectables launched, they carried list prices exceeding $14,000 per year, leading to strict insurance prior authorizations and high rejection rates.[3][5]

Merck has set the list price for Lipfendra at $315 per month, or roughly $3,780 annually. This is approximately half the list price of some competing injectable PCSK9 products, positioning the oral therapy to potentially bypass some of the payer friction that stunted the class's early growth.[3]

Patient advocacy groups have welcomed the approval as a matter of health equity. The Family Heart Foundation noted that a substantial share of primary care physicians have never prescribed an injectable PCSK9 inhibitor, often leaving high-risk patients reliant solely on statins. A daily pill is expected to be much more readily adopted by general practitioners.[4][7]

The FDA expedited Lipfendra's review using a Commissioner's National Priority Voucher, a program designed to accelerate the availability of medicines that align with critical public health needs. Cardiovascular disease remains the leading cause of death globally, making the management of modifiable risk factors like LDL cholesterol a top priority.[1]

While the cholesterol-lowering data is definitive, one major clinical question remains unanswered. The FDA approval is based on the surrogate endpoint of LDL reduction, but Merck is still conducting a massive, multi-year cardiovascular outcomes trial to prove that Lipfendra actually prevents heart attacks, strokes, and cardiovascular deaths.[3][5]

Given that the injectable PCSK9 inhibitors have already proven they reduce cardiovascular events, most cardiologists expect the oral version to show similar long-term benefits. Until those results are published, however, the exact magnitude of the drug's life-saving potential remains a well-educated hypothesis.[3][5]

The commercial stakes for Merck are immense. The pharmaceutical giant is bracing for the impending patent expiration of its blockbuster cancer drug Keytruda, and analysts project Lipfendra could reach $5 billion in peak annual sales to help fill that revenue gap.[3]

Merck will not have the oral PCSK9 market to itself for long. Competitors, including AstraZeneca with its candidate AZD0780, are rapidly advancing their own oral formulations through clinical trials. For now, however, Lipfendra stands alone as the first needle-free option in a drug class that could redefine preventative cardiology.[3]